News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) May Share Avastin Brain Cancer Data Amid Conflicting Results



2/20/2014 8:12:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Roche Holding AG (ROG) and a group of outside investigators may share raw data from conflicting trials of Avastin to help determine whether the $7 billion-a-year treatment really helps patients with deadly brain cancer. The data is from two trials that both found the drug didn’t help patients with glioblastoma live longer, but differed on a more subjective measure: quality of life. In results published today in the New England Journal of Medicine, researchers who led a Roche-sponsored trial said Avastin improved or maintained quality of life and brain function.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES